Bacterial DNA gyrase is a well-established and clinically validated target to develop novel antibacterial.
Due to early crystallographic evidence, plasmepsin II (Plm II) emerged as well explored target to develop novel antimalarials as well as a starting point to develop inhibitors targeting some other subtypes of plasmepsins i.e. Plm I, II, IV and V.
ftsZ (Rv2150c), a bacterial tubulin homologue involved in essential cell division, is considered as an attractive target to develop novel anti-TB drugs, as well as new broad-spectrum antibacterial agents [40].
Thus, Na,K-ATPase might serve as a valid target to develop novel therapeutic approaches in tumors with aberrant activation of the EGFR signaling cascades.
While cardiac glycosides might not prove useful in all tumor types as anticancer therapeutics, we suggest that Na,K-ATPase is an attractive target to develop novel therapeutic strategies for medulloblastoma with aberrant activation of EGFR signaling.
Specific inhibition of sPLA2 IIa may, therefore, be a valid target to develop novel disease modifying anti-rheumatic drugs (DMARDs) which are more efficacious than existing therapies, given high concentrations of sPLA2 IIa in arthritic joints [ 23].
